Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

306 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FDG PET Hybrid Imaging.
Becker J, Schwarzenböck SM, Krause BJ. Becker J, et al. Among authors: krause bj. Recent Results Cancer Res. 2020;216:625-667. doi: 10.1007/978-3-030-42618-7_19. Recent Results Cancer Res. 2020. PMID: 32594401 Review.
Prospective evaluation of [11C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer.
Schwarzenböck SM, Eiber M, Kundt G, Retz M, Sakretz M, Kurth J, Treiber U, Nawroth R, Rummeny EJ, Gschwend JE, Schwaiger M, Thalgott M, Krause BJ. Schwarzenböck SM, et al. Among authors: krause bj. Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2105-2113. doi: 10.1007/s00259-016-3439-9. Epub 2016 Jun 17. Eur J Nucl Med Mol Imaging. 2016. PMID: 27317482 Clinical Trial.
[11C]Choline PET/CT in therapy response assessment of a neoadjuvant therapy in locally advanced and high risk prostate cancer before radical prostatectomy.
Schwarzenböck SM, Knieling A, Souvatzoglou M, Kurth J, Steiger K, Eiber M, Esposito I, Retz M, Kübler H, Gschwend JE, Schwaiger M, Krause BJ, Thalgott M. Schwarzenböck SM, et al. Among authors: krause bj. Oncotarget. 2016 Sep 27;7(39):63747-63757. doi: 10.18632/oncotarget.11653. Oncotarget. 2016. PMID: 27572317 Free PMC article.
Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions.
Fanti S, Minozzi S, Morigi JJ, Giesel F, Ceci F, Uprimny C, Hofman MS, Eiber M, Schwarzenbock S, Castellucci P, Bellisario C, Chauvie S, Bergesio F, Emmett L, Haberkorn U, Virgolini I, Schwaiger M, Hicks RJ, Krause BJ, Chiti A. Fanti S, et al. Among authors: krause bj. Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1622-1635. doi: 10.1007/s00259-017-3725-1. Epub 2017 May 23. Eur J Nucl Med Mol Imaging. 2017. PMID: 28536833
[68Ga]pentixafor for CXCR4 imaging in a PC-3 prostate cancer xenograft model - comparison with [18F]FDG PET/CT, MRI and ex vivo receptor expression.
Schwarzenböck SM, Stenzel J, Otto T, Helldorff HV, Bergner C, Kurth J, Polei S, Lindner T, Rauer R, Hohn A, Hakenberg OW, Wester HJ, Vollmar B, Krause BJ. Schwarzenböck SM, et al. Among authors: krause bj. Oncotarget. 2017 Sep 16;8(56):95606-95619. doi: 10.18632/oncotarget.21024. eCollection 2017 Nov 10. Oncotarget. 2017. PMID: 29221153 Free PMC article.
Evaluation of [68Ga]Ga-PSMA PET/CT for therapy response assessment of [177Lu]Lu-PSMA radioligand therapy in metastasized castration refractory prostate cancer and correlation with survival.
Kurth J, Kretzschmar J, Aladwan H, Heuschkel M, Gummesson A, Bergner C, Kundt G, Hakenberg OW, Krause BJ, Schwarzenböck SM. Kurth J, et al. Among authors: krause bj. Nucl Med Commun. 2021 Nov 1;42(11):1217-1226. doi: 10.1097/MNM.0000000000001446. Nucl Med Commun. 2021. PMID: 34424870
306 results